Philippe Cinquin

Prof. Philippe Cinquin


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2022 in Sensors
Verified
Journal Article
Open access
PDF file
TSThomas Soranzo
Thomas Soranzo
ATAwatef Ben Tahar
Awatef Ben Tahar
ACAyman Chmayssem
Ayman Chmayssem
MZMarc Zelsmann
Marc Zelsmann
Pankaj VadgamaPankaj Vadgama
Pankaj Vadgama
AZAbdelkader Zebda
Abdelkader Zebda
In this work, the enzyme aldehyde reductase, also known as aldose reductase, was synthesized and cloned from a human gene. Spectrophotometric measurements show that in presence of the nicotinamide adenine dinucleotide phosphate cofactor (NADPH), the aldehyde reductase catalyzed the reduction of glucose to sorbitol. Electrochemical measurements performed on an electrodeposited poly(methylene green)-modified gold electrode showed that in the presence of the enzyme aldehyde reductase, the electrocatalytic oxidation current of NADPH decreased drastically after the addition of glucose. These results demonstrate that aldehyde reductase is an enzyme that allows the construction of an efficient electrochemical glucose biosensor based on glucose reduction.

7 August 2024 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
SSSalomez-Ihl Salomez-Ihl
Salomez-Ihl Salomez-Ihl
JGJ. Giai
J. Giai
MBM. Barbado
M. Barbado
APA. Paris
A. Paris
STS. Touati
S. Touati
JBJ. P. Brion
J. P. Brion
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has triggered a serious global health crisis, resulting in millions of reported deaths since its initial identification in China in November 2019. The global disparities in immunization access emphasize the urgent need for ongoing research into therapeutic interventions. This study focuses on the potential use of molecular dihydrogen (H2) inhalation as an adjunctive treatment for COVID-19. H2 therapy shows promise in inhibiting intracellular signaling pathways associated with inflammation, particularly when administered early in conjunction with nasal oxygen therapy. This phase I study, characterized by an open-label, prospective, monocentric, and single ascending-dose design, seeks to assess the safety and tolerability of the procedure in individuals with confirmed SARS-CoV-2 infection. Employing a 3 + 3 design, the study includes three exposure durations (target durations): 1 day (D1), 3 days (D2), and 6 days (D3). We concluded that the maximum tolerated duration is at least 3 days. Every patient showed clinical improvement and excellent tolerance to H2 therapy. To the best of our knowledge, this phase I clinical trial is the first to establish the safety of inhaling a mixture of H2 (3.6%) and N2 (96.4%) in hospitalized COVID-19 patients. The original device and method employed ensure the absence of explosion risk. The encouraging outcomes observed in the 12 patients included in the study justify further exploration through larger, controlled clinical trials. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04633980 .

17 January 2025 in ISME Communications
Verified
Journal Article
Open access
ATAlexandre Tronel
Alexandre Tronel
MRMorgane Roger-Margueritat
Morgane Roger-Margueritat
CPCaroline Plazy
Caroline Plazy
SBSalomé Biennier
Salomé Biennier
ACAnthony Craspay
Anthony Craspay
AGaudrey LE GOUELLEC
audrey LE GOUELLEC
Because accessing the small intestine is technically challenging, studies of the small intestinal microbiome are predominantly conducted in patients rather than in healthy individuals. Invasive clinical procedures, such as endoscopy or surgery, usually performed for therapeutic purposes, are typically required for sample collection. Although stomas offer a less invasive means for repeated sampling, their use remains restricted to patient populations. As a result, the small intestinal microbiome of healthy individuals remains largely understudied. This study evaluated a novel ingestible medical device for collecting luminal samples from the small intestine. A monocentric interventional trial (NCT05477069) was conducted on 15 healthy subjects. Metagenomics, metabolomics, and culturomics were used to assess the effectiveness of the medical device in characterizing the healthy small intestinal microbiome and identifying potential biomarkers. The small intestinal microbiota differed significantly from the fecal microbiota, displaying high inter-individual variability, lower species richness and reduced alpha diversity. A combined untargeted and semi-targeted LC–MS/MS metabolomics approach identified a distinct small intestinal metabolic footprint, with bile acids and amino acids being the most abundant metabolite classes. Host- and host/microbe-derived bile acids were particularly abundant in small intestinal samples. Using a fast culturomics approach on two small intestinal samples, we achieved species-level characterization and identified 90 bacterial species, including five potentially novel ones. This study demonstrates the efficacy of our novel sampling device in enabling comprehensive small intestinal microbiome analysis through an integrative, multi-omics approach. This approach allows distinct microbiome signatures to be identified between small intestinal and fecal samples.

23 April 2020 in Applied Sciences
Verified
Journal Article
Open access
PDF file
JAJean-Pierre Alcaraz
Jean-Pierre Alcaraz
GMGauthier Menassol
Gauthier Menassol
GPGéraldine Penven
Géraldine Penven
JTJacques Thélu
Jacques Thélu
SISarra El Ichi
Sarra El Ichi
DMDonald Keith Martin
Donald Keith Martin
We discuss the perspectives of designing implantable medical devices that have the criterion of being symbiotic. Our starting point was whether the implanted device is intended to have any two-way (“duplex”) communication of energy or materials with the body. Such duplex communication extends the existing concepts of a biomaterial and biocompatibility to include the notion that it is important to consider the intended functional use of the implanted medical device. This demands a biomimetic approach to design functional symbiotic implantable medical devices that can be more efficient in mimicking what is happening at the molecular and cellular levels to create stable interfaces that allow for the unfettered exchanges of molecules between an implanted device and a body. Such a duplex level of communication is considered to be a necessary characteristic of symbiotic implanted medical devices that are designed to function for long periods of time inside the body to restore and assist the function of the body. We illustrate these perspectives with experience gained from implanting functional enzymatic biofuel cells.

Verified
Journal Article
Open access
PDF file
YGYoann GABOREAU
Yoann GABOREAU
AMAleksandra Milovancev
Aleksandra Milovancev
CRCarole Rolland
Carole Rolland
CEClaire Eychenne
Claire Eychenne
JAJean-Pierre Alcaraz
Jean-Pierre Alcaraz
JBJean-Luc Bosson
Jean-Luc Bosson
Background. Due to its antioxidant, anti-inflammatory, anti-apoptosis, and anti-fatigue properties, molecular hydrogen (H2) is potentially a novel therapeutic nutrient for patients with coronavirus acute disease 2019 (COVID-19). We determined the efficacy and safety profile of hydrogen-rich water (HRW) to reduce the risk of COVID-19 progression. Methods: We also conducted a phase 3, triple-blind, randomised, placebo-controlled trial to evaluate treatment with HRW initiated within 5 days after the onset of signs or symptoms in primary care patients with mild-to-moderate, laboratory-confirmed COVID-19. Participants were randomised to receive HRW or placebo twice daily for 21 days. The incidence of clinical worsening and adverse events were the primary endpoints. Results: A total of 675 participants were followed up to day 30. HRW was not superior to placebo in preventing clinical worsening at day 14: in H2 group, 46.1% in the H2 group, 43.5% in the placebo group, hazard ratio 1.09, 90% confidence interval [0.90–1.31]. One death was reported at day 30 in the H2 group and two in the placebo group at day 30. Adverse events were reported in 91 (27%) and 89 (26.2%) participants, respectively. Conclusions: HRW taken twice daily from the onset of COVID-19 symptoms for 21 days did not reduce clinical worsening.

1 January 2019
Verified
Book Chapter
Open access
PDF file
GPGuiral Pierrick
Guiral Pierrick
PPPittet Patrick
Pittet Patrick
GYGrondin Yannick
Grondin Yannick
JPJalade Patrice
Jalade Patrice
GJGalvan Jean-Marc
Galvan Jean-Marc
PCPhilippe Cinquin
Philippe Cinquin
Personalized medicine implies reducing invasiveness of therapeutic procedures. Although interventional radiology proved a very interesting alternative to surgical procedures, it still raises concerns due to the irradiation dose received by the medical team (and by the patient). We propose a novel concept allowing to reduce very significantly the irradiation dose during the phases where tools inserted in the patient have to be tracked with respect to previously acquired images. This implies inserting a miniaturized X-ray detector in the tip of the tools, and reducing the dose by a "rotating collimator". We demonstrate that real-time processing of the signals allows accurate localization of the tip of the tools, with a dose reduction of at least ten times.